Investments & digital assets › F8949.D.X106
F8949.D.X106 · federal · F8949 line D.X106
Delmar Pharma (acquired 2024-10-09, sold 2025-10-24; proceeds 1,514.10, basis 1,776.55)
-262.45
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 22 · field X106_desc · “Lot X106 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 22 · field X106_acq · “Lot X106 date acquired”
read as “10/09/2024” → 2024-10-09
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 22 · field X106_sold · “Lot X106 date sold”
read as “10/24/2025” → 2025-10-24
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 22 · field X106_proceeds · “Lot X106 proceeds”
read as “1,514.10” → 1,514.10
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 22 · field X106_basis · “Lot X106 cost basis”
read as “1,776.55” → 1,776.55
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 22 · field X106_wash · “Lot X106 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: -262.45v2 · 2026-03-19: -262.45v3 · 2026-06-23: -262.45
Adjust this number
Evidence & discussion
Record how you verified it